A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3.

chronic kidney disease epidemiology genetics nephrocalcinosis oxalate primary hyperoxaluria type 3 urolithiasis

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
09 2021
Historique:
received: 25 09 2020
revised: 04 03 2021
accepted: 11 03 2021
pubmed: 19 4 2021
medline: 26 8 2021
entrez: 18 4 2021
Statut: ppublish

Résumé

Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH's with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 patients, 74 were followed over a median of six years. Median age of first symptoms and diagnosis were 1.9 and 6.3 years, respectively. Urolithiasis was the major clinical feature observed in 70% of pediatric and 50% of adult patients. At most recent follow-up available for 56 of the 95 patients, 21.4% were in chronic kidney disease stages 2 or more. For better characterization, samples from 49 patients were analyzed in a single laboratory and compared to data from patients with PH1 and PH2 from the same center. Urinary oxalate excretion was not significantly different from PH1 and PH2 (median: 1.37, 1.40 and 1.16 mmol/1.73m

Identifiants

pubmed: 33865885
pii: S0085-2538(21)00386-0
doi: 10.1016/j.kint.2021.03.031
pii:
doi:

Substances chimiques

Oxalates 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

621-635

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Cristina Martin-Higueras (C)

Department of Basic Medical Sciences, Institute of Biomedical Technologies, University of La Laguna, Centre for Biomedical Research in Rare Diseases (CIBERER), Tenerife, Spain.

Sander F Garrelfs (SF)

Department of Pediatric Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Jaap W Groothoff (JW)

Department of Pediatric Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Dorrit E Jacob (DE)

Research School of Earth Sciences, ANU College of Science, The Australian National University, Canberra, Australia.

Shabbir H Moochhala (SH)

University College London, Department of Renal Medicine, Royal Free Hospital, London, UK.

Justine Bacchetta (J)

Center of Reference for Rare Renal Diseases, Hospices Civils de Lyon, Centre Hospitalier Universitaire de Lyon, Bron, France.

Cecile Acquaviva (C)

Center of Reference for Rare Renal Diseases, Hospices Civils de Lyon, Centre Hospitalier Universitaire de Lyon, Bron, France.

Marcin Zaniew (M)

Department of Pediatrics, University of Zielona Góra, Zielona Góra, Poland.

Przymyslaw Sikora (P)

Department of Pediatric Nephrology, Medical University of Lublin, Lublin, Poland.

Bodo B Beck (BB)

Department of Human Genetics, University Hospital Cologne, Cologne, Germany; Outpatient Clinics, German Hyperoxaluria Center, Cologne/Bonn, Germany; Center for Molecular Medicine, University Hospital, Cologne, Germany.

Bernd Hoppe (B)

Outpatient Clinics, German Hyperoxaluria Center, Cologne/Bonn, Germany. Electronic address: bhoppe@hyperoxaluria-center.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH